Checkpoint inhibitor immunotherapy (CPI), especially programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) blockade, can reinvigorate the preexisting anti-tumor immunity to achieve a durable response rate, making it an important combination therapy in a post-RFA tumor recurrence. This evidence concerns the gene PDCD1 and neoplasm.